Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
-
Published:2024-08
Issue:2
Volume:91
Page:300-311
-
ISSN:0190-9622
-
Container-title:Journal of the American Academy of Dermatology
-
language:en
-
Short-container-title:Journal of the American Academy of Dermatology
Author:
Zhang Junfen, Boesjes Celeste M., Loman Laura, Kamphuis Esmé, Romeijn Margreet L.E., Spekhorst Lotte S., Haeck Inge, van der Gang Lian F., Dekkers Coco C., van der Rijst Lisa P., Oosting Albert J., van Lumig Paula, van Lynden-van Nes Anneke M.T., Tupker Ron A., Nijssen Annieke, Flinterman Annebeth, Politiek Klaziena, Touwslager Wouter R.H., Christoffers Wianda A., Stewart Shiarra M., Kamsteeg Marijke, de Graaf Marlies, de Bruin-Weller Marjolein S., Schuttelaar Marie-Louise A.ORCID
Funder
Pfizer Inc Sanofi US Leo Pharma AS Eli Lilly and Co
Reference41 articles.
1. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy;Wollenberg;J Eur Acad Dermatol Venereol,2022 2. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial;Blauvelt;Lancet,2017 3. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study;Deleuran;J Am Acad Dermatol,2020 4. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis;Beck;Am J Clin Dermatol,2022 5. Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study;Pagan;J Allergy Clin Immunol Pract,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|